Results 71 to 80 of about 1,118 (255)
Molecular Oncology, EarlyView.CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
WITHDRAWN: Double Rarity: Malignant Masquerade Biliary Stricture in a Situs Inversus Totalis Patient. A Case Report [PDF]
, 2020 Katalin Eitler +7 more
openalex +1 more source
Rare birds in Slovenia in 2016 – Slovenian Rarities Committee Report [PDF]
Acrocephalus, 2017 Summary This report by the Slovenian Rarities Committee presents records of rare bird species in Slovenia in 2016, with some addenda for previous years. The numbers in brackets refer to the number of records (first number) and individuals (second number) recorded between 1 Jan 1950 and 31 Dec 2015.
openaire +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Rare birds in Slovenia in 2015 – Slovenian Rarities Committee’s Report [PDF]
Acrocephalus, 2016 Summary This report by the Slovenian Rarities Committee presents records of rare bird species in Slovenia in 2015, with some addenda for previous years. The numbers in brackets refer to the number of records (first number) and individuals (second number) recorded between 1 Jan 1950 and 31 Dec 2014.
openaire +1 more source
Molecular Oncology, EarlyView.Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad +12 more
wiley +1 more source
Molecular Oncology, EarlyView.We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck +12 more
wiley +1 more source
Strength through diversity: how cancers thrive when clones cooperate
Molecular Oncology, EarlyView.Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken +3 more
wiley +1 more source
Desmoplastic ameloblastoma of anterior mandible: Case report of a rarity
Journal of Indian Academy of Oral Medicine and Radiology, 2008 Ameloblastoma, one of the most common odontogenic tumors of the jaws, presents classical clinical, radiographic and histopathological diagnostic features exhibiting a benign but locally aggressive and destructive clinical course with a high rate of recurrence. A case of desmoplastic ameloblastoma of mandible is discussed in this article, which presents
openaire +2 more sources
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source